Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAZAN: Zanubrutinib-based Induction and Maintenance in Treatment-Naïve Mantle Cell Lymphoma
NCT06854003Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Nov 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, sonrotoclax in mantle cell lymphoma (MCL). Started Apr 2025; status: recruiting.
02
Drugs
zanubrutinibsonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06854003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854003.